210 related articles for article (PubMed ID: 30228296)
1. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.
Chiou SH; Dorsch M; Kusch E; Naranjo S; Kozak MM; Koong AC; Winslow MM; Grüner BM
Sci Rep; 2018 Sep; 8(1):14008. PubMed ID: 30228296
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
[TBL] [Abstract][Full Text] [Related]
3. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Xu P; Yao J; He J; Zhao L; Wang X; Li Z; Qian J
Oncotarget; 2016 Mar; 7(12):14831-40. PubMed ID: 26894380
[TBL] [Abstract][Full Text] [Related]
4. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
5. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
6. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC.
Strell C; Norberg KJ; Mezheyeuski A; Schnittert J; Kuninty PR; Moro CF; Paulsson J; Schultz NA; Calatayud D; Löhr JM; Frings O; Verbeke CS; Heuchel RL; Prakash J; Johansen JS; Östman A
Br J Cancer; 2017 Jun; 117(1):65-77. PubMed ID: 28524160
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
[TBL] [Abstract][Full Text] [Related]
9. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma.
Piscuoglio S; Zlobec I; Pallante P; Sepe R; Esposito F; Zimmermann A; Diamantis I; Terracciano L; Fusco A; Karamitopoulou E
Histopathology; 2012 Feb; 60(3):397-404. PubMed ID: 22276603
[TBL] [Abstract][Full Text] [Related]
10. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
11. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma.
Sugimoto T; Iwagami Y; Kobayashi S; Yamanaka C; Sasaki K; Yamada D; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
Ann Surg Oncol; 2024 Jun; 31(6):3718-3736. PubMed ID: 38502294
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression.
Dangi-Garimella S; Sahai V; Ebine K; Kumar K; Munshi HG
PLoS One; 2013; 8(5):e64566. PubMed ID: 23696899
[TBL] [Abstract][Full Text] [Related]
14. Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression.
Nishino H; Takano S; Yoshitomi H; Suzuki K; Kagawa S; Shimazaki R; Shimizu H; Furukawa K; Miyazaki M; Ohtsuka M
Cancer Med; 2017 Nov; 6(11):2686-2696. PubMed ID: 28960866
[TBL] [Abstract][Full Text] [Related]
15. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
16. Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma.
Binenbaum Y; Fridman E; Yaari Z; Milman N; Schroeder A; Ben David G; Shlomi T; Gil Z
Cancer Res; 2018 Sep; 78(18):5287-5299. PubMed ID: 30042153
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
18. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
19. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
20. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
Panzeri V; Manni I; Capone A; Naro C; Sacconi A; Di Agostino S; de Latouliere L; Montori A; Pilozzi E; Piaggio G; Capurso G; Sette C
Mol Oncol; 2021 Feb; 15(2):579-595. PubMed ID: 33159833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
